-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Imeglimin is the first in a new tetrahydrotriazine-containing class of oral antidiabetic agents, the glimins. It has been shown to act on the liver, muscle and pancreatic β-cells to uniquely target the key defects of type 2 diabetes.
-
- Properties
-
Overview